A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?

被引：0

作者：

Paolo Antonetti

Maria Concetta Fargnoli

Giampiero Porzio

Lisa Salvatore

Roberto Filippi

Michele Ghidini

Olga Nigro

Fabio Gelsomino

Ina Valeria Zurlo

Emanuela Dell’Aquila

Pasquale Lombardi

Susana Roselló Keränen

Ilaria Depetris

Riccardo Giampieri

Cristina Morelli

Michele De Tursi

Francesca Romana Di Pietro

Nicoletta Zanaletti

Pasquale Vitale

Ingrid Garajova

Gian Paolo Spinelli

Federica Zoratto

Michela Roberto

Angelica Petrillo

Giacomo Aimar

Alessio Cortellini

Maria Vittoria Pensieri

Corrado Ficorella

Claudio Ferri

Alessandro Parisi

机构：

[1] Dermatology,Department of Biotechnological and Applied Clinical Sciences

[2] St. Salvatore Hospital,Medical Oncology, Comprehensive Cancer Center

[3] University of L’Aquila,Department of Oncology

[4] Medical Oncology,Centro Oncologico Ematologico Subalpino

[5] St. Salvatore Hospital,Department of Oncology and Hematology

[6] Università Cattolica del Sacro Cuore,Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute

[7] Fondazione Policlinico Universitario Agostino Gemelli,Clinica Oncologica e Centro Regionale di Genetica Oncologica

[8] IRCCS,Medical Oncology Unit and PhD program in Systems and Experimental Medicine (XXXV cycle)

[9] University of Turin,Department of Medical, Oral and Biotechnological Sciences and Center for Advance Studies and Technology (CAST)

[10] Division of Medical Oncology,Department of Precision Medicine

[11] Candiolo Cancer Institute,Department of Clinical and Molecular Medicine

[12] FPO – IRCCS,Department of Life, Health and Environmental Sciences

[13] Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino,undefined

[14] Medical Oncology Unit,undefined

[15] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,undefined

[16] Medical Oncology,undefined

[17] ASST Sette Laghi,undefined

[18] Ospedale di Circolo e Fondazione Macchi,undefined

[19] Division of Oncology,undefined

[20] University Hospital of Modena,undefined

[21] Medical Oncology,undefined

[22] “Vito Fazzi” Hospital,undefined

[23] Medical Oncology 1,undefined

[24] IRCCS Regina Elena National Cancer Institute,undefined

[25] University of Valencia,undefined

[26] CIBERONC,undefined

[27] Instituto de Salud Carlos III,undefined

[28] Medical Oncology,undefined

[29] ASL TO4,undefined

[30] Ospedale Civile di Ivrea,undefined

[31] Università Politecnica delle Marche,undefined

[32] AOU Ospedali Riuniti,undefined

[33] Tor Vergata University Hospital,undefined

[34] G. D’Annunzio University,undefined

[35] Clinical Oncology Unit,undefined

[36] S.S. Annunziata Hospital,undefined

[37] IRCCS Istituto Dermopatico dell’Immacolata (IDI),undefined

[38] Experimental Clinical Abdominal Oncology Unit,undefined

[39] Istituto Nazionale Tumori-IRCCS-Fondazione G.Pascale,undefined

[40] Università della Campania “Luigi Vanvitelli”,undefined

[41] Medical Oncology Unit,undefined

[42] Santa Chiara Hospital,undefined

[43] Medical Oncology Unit,undefined

[44] University Hospital of Parma,undefined

[45] UOC Territorial Oncology - AUSL Latina-CdS Aprilia – University of Rome “Sapienza”,undefined

[46] Medical Oncology,undefined

[47] Santa Maria Goretti Hospital,undefined

[48] Sapienza University of Rome,undefined

[49] Oncology Unit,undefined

[50] Sant’Andrea Hospital,undefined

来源：

Supportive Care in Cancer | 2022年 / 30卷

关键词：

mCRC; Acneiform rash; Pre-emptive; Reactive; Paronychia; Panitumumab; Cetuximab; Anti-EGFR;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2455 / 2465

页数：10

共 50 条

[31] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
Graham, Christopher N.
Hechmati, Guy
Fakih, Marwan G.
Knox, Hediyyih N.
Maglinte, Gregory A.
Hjelmgren, Jonas
Barber, Beth
Schwartzberg, Lee S.
JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
[32] First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study
Mendez Mendez, Jose Carlos
Salgado Fernandez, Mercedes
de la Camara Gomez, Juan
Pellon Augusto, Mari Luz
Covela Rua, Marta
Quintero Aldana, Guillermo
Fernandez Montes, Ana
Reboredo Lopez, Margarida
Valladares Ayerbes, Manuel
Jorge Fernandez, Monica
Gonzalez Villarroel, Paula
Romero Reinoso, Carlos
Ramos Vazquez, Manuel
JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1263 - 1267
[33] First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
Pietrantonio, Filippo
Cremolini, Chiara
Petrelli, Fausto
Di Bartolomeo, Maria
Loupakis, Fotios
Maggi, Claudia
Antoniotti, Carlotta
de Braud, Filippo
Falcone, Alfredo
Iacovelli, Roberto
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (01) : 156 - 166
[34] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
Hitoshi Soda
Hiromichi Maeda
Junichi Hasegawa
Takao Takahashi
Shoichi Hazama
Mutsumi Fukunaga
Emiko Kono
Masahito Kotaka
Junichi Sakamoto
Naoki Nagata
Koji Oba
Hideyuki Mishima
BMC Cancer, 15
[35] Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study
Liang, Yi-Hsin
Chen, Kuo-Hsing
Shao, Yu-Yun
CANCER MEDICINE, 2023, 12 (14): : 15176 - 15186
[36] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
Uemura, Mamoru
Kim, Ho Min
Hata, Tsuyoshi
Sakata, Kazuya
Okuyama, Masaki
Takemoto, Hiroyoshi
Fujii, Hitoshi
Fukuzaki, Takayuki
Morita, Tetsushi
Hata, Taishi
Takemasa, Ichiro
Satoh, Taroh
Mizushima, Tsunekazu
Doki, Yuichiro
Mori, Maski
MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) : 375 - 379
[37] Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial
Avallone, Antonio
Giuliani, Francesco
De Stefano, Alfonso
Santabarbara, Giuseppe
Nasti, Guglielmo
Montesarchio, Vincenzo
Rosati, Gerardo
Cassata, Antonino
Leo, Silvana
Romano, Carmela
Tamburini, Emiliano
Silvestro, Lucrezia
Lotesoriere, Claudio
Nappi, Anna
Santini, Daniele
Petrillo, Antonella
Colombo, Alfredo
Febbraro, Antonio
Leone, Alessandra
Mannavola, Francesco
Laterza, Maria Maddalena
Izzo, Francesco
Sobrero, Alberto
Delrio, Paolo
Giannarelli, Diana
Budillon, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07) : 829 - 839
[38] Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/ BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment
Zhou, Yu-Wen
Zhao, Xin
Ni, Lu
Cao, Peng
Leng, Wei-Bing
Zhu, Qing
Gou, Hong-Feng
Zhang, Jiao
Li, Xiao-Fen
Qiu, Meng
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 131
[39] Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with RAS Wild-Type Left-Sided Tumours in Canada
Boyne, Devon J.
Ngan, Elaine
Carbonell, Chantelle
Wani, Rajvi J.
Morris, Carlye Cirone
Martinez, Daniel Jun
Cheung, Winson Y.
CURRENT ONCOLOGY, 2023, 30 (09) : 8220 - 8232
[40] The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis
Ciliberto, Domenico
Staropoli, Nicoletta
Caglioti, Francesca
Chiellino, Silvia
Ierardi, Antonella
Ingargiola, Rossana
Botta, Cirino
Arbitrio, Mariamena
Correale, Pierpaolo
Tassone, Pierfrancesco
Tagliaferri, Pierosandro
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 69 - 77

← 1 2 3 4 5 →